The U.S. Food and Drug Administration (FDA) approved the drug Tekamlo to treat high blood pressure, made by pharmaceutical manufacturer Novartis of East Hanover, New Jersey. Tekamlo tablets combine the renin inhibitor aliskiren with the calcium channel blocker amlodipine.
FDA approved Tekamlo as an initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.
Novartis says the FDA approval of Tekamlo was based on clinical trial data involving more than 5,000 patients with mild-to-moderate high blood pressure. According to the Centers for Disease Control about one in three U.S. adults (32%) have hypertension. If left untreated, high blood pressure can lead to stroke, heart attack and heart failure.
RSS - Posts